ID: ALA1276882

Max Phase: Preclinical

Molecular Formula: C22H20F3N5O3

Molecular Weight: 459.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCc1cccnc1N1CCOCC1)c1cncc(-c2ccc(OC(F)(F)F)cc2)n1

Standard InChI:  InChI=1S/C22H20F3N5O3/c23-22(24,25)33-17-5-3-15(4-6-17)18-13-26-14-19(29-18)21(31)28-12-16-2-1-7-27-20(16)30-8-10-32-11-9-30/h1-7,13-14H,8-12H2,(H,28,31)

Standard InChI Key:  RNUQEWXMJUEUKA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 459.43

Molecular Weight (Monoisotopic): 459.1518

AlogP: 3.20

#Rotatable Bonds: 6

Polar Surface Area: 89.47

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.82

CX Basic pKa: 6.13

CX LogP: 3.45

CX LogD: 3.43

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.61

Np Likeness Score: -1.81

References

1. Scanio MJ, Shi L, Drizin I, Gregg RJ, Atkinson RN, Thomas JB, Johnson MS, Chapman ML, Liu D, Krambis MJ, Liu Y, Shieh CC, Zhang X, Simler GH, Joshi S, Honore P, Marsh KC, Knox A, Werness S, Antonio B, Krafte DS, Jarvis MF, Faltynek CR, Marron BE, Kort ME..  (2010)  Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.,  18  (22): [PMID:20965738] [10.1016/j.bmc.2010.09.057]

2. Bagal SK, Brown AD, Cox PJ, Omoto K, Owen RM, Pryde DC, Sidders B, Skerratt SE, Stevens EB, Storer RI, Swain NA..  (2013)  Ion channels as therapeutic targets: a drug discovery perspective.,  56  (3): [PMID:23121096] [10.1021/jm3011433]

Source

Source(1):

• Scientific Literature